Related Experiment Video

Updated: Jul 29, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.4K

MicroRNAs as regulators of tumor metabolism

Francesca Ruggieri1,2, Katharina Jonas1,2, Manuela Ferracin3

  • 1Division of Oncology, Medical University of Graz, Graz, Austria.

Endocrine-Related Cancer
|May 24, 2023
PubMed

Insights

Cancer cells alter their metabolism for growth, a process regulated by microRNAs. These microRNAs can be biomarkers and therapeutic targets for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer cells exhibit metabolic reprogramming, including altered lactate, glutamine, and lipid metabolism, to fuel rapid growth and biosynthesis.
  • MicroRNAs, small non-coding RNAs, regulate diverse biological pathways and are implicated in various diseases, including cancer.
  • Dysregulated microRNA expression is common in cancer, with tumor suppressors targeting metabolic pathways often downregulated.

Approach:

  • This review synthesizes recent research on microRNAs that regulate cancer cell metabolism.
  • It examines the role of microRNAs in metabolic alterations characteristic of tumors.
  • The focus is on microRNAs as potential diagnostic biomarkers and therapeutic targets in oncology.

Key Points:

  • MicroRNAs play a crucial role in controlling metabolic pathways essential for cancer cell proliferation.
  • Downregulation of tumor suppressor microRNAs targeting metabolic genes is a hallmark of many cancers.
  • Specific microRNAs are being investigated for their potential as biomarkers for early cancer detection and prognosis.

Conclusions:

  • MicroRNAs are critical regulators of cancer metabolism, offering new avenues for therapeutic intervention.
  • Targeting microRNAs involved in metabolic reprogramming presents a promising strategy for novel cancer treatments.
  • Further research into microRNA-metabolism interactions could lead to improved diagnostic tools and therapies for cancer patients.
Keywords:
cancermicroRNAssmall non-coding RNAstumor metabolism

More Related Videos

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.4K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K